CN104367946A - 一种治疗慢性子宫内膜炎的中药栓剂及其制备方法 - Google Patents
一种治疗慢性子宫内膜炎的中药栓剂及其制备方法 Download PDFInfo
- Publication number
- CN104367946A CN104367946A CN201410620655.9A CN201410620655A CN104367946A CN 104367946 A CN104367946 A CN 104367946A CN 201410620655 A CN201410620655 A CN 201410620655A CN 104367946 A CN104367946 A CN 104367946A
- Authority
- CN
- China
- Prior art keywords
- parts
- suppository
- radix
- chinese medicine
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 98
- 239000000829 suppository Substances 0.000 title claims abstract description 68
- 208000030373 chronic endometritis Diseases 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims description 28
- 229940079593 drug Drugs 0.000 claims abstract description 29
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims abstract description 23
- 241000746375 Andrographis Species 0.000 claims abstract description 18
- 210000000582 semen Anatomy 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 238000010438 heat treatment Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000000758 substrate Substances 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 13
- 229920000742 Cotton Polymers 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 10
- 238000002844 melting Methods 0.000 claims description 10
- 230000008018 melting Effects 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- 238000007493 shaping process Methods 0.000 claims description 10
- 238000010410 dusting Methods 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 238000002481 ethanol extraction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000013618 particulate matter Substances 0.000 claims description 5
- 229960000502 poloxamer Drugs 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- 230000008016 vaporization Effects 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 229920003023 plastic Polymers 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 3
- 239000013521 mastic Substances 0.000 claims description 3
- 238000001256 steam distillation Methods 0.000 claims description 3
- 241000334154 Isatis tinctoria Species 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 81
- 210000004369 blood Anatomy 0.000 abstract description 78
- 230000000694 effects Effects 0.000 abstract description 50
- 208000002193 Pain Diseases 0.000 abstract description 40
- 230000036407 pain Effects 0.000 abstract description 38
- 208000004145 Endometritis Diseases 0.000 abstract description 29
- 230000001737 promoting effect Effects 0.000 abstract description 23
- 206010061218 Inflammation Diseases 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 230000036039 immunity Effects 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 4
- 230000002357 endometrial effect Effects 0.000 abstract description 3
- 235000011034 Rubus glaucus Nutrition 0.000 abstract description 2
- 244000235659 Rubus idaeus Species 0.000 abstract description 2
- 235000009122 Rubus idaeus Nutrition 0.000 abstract description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 abstract 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 235000013717 Houttuynia Nutrition 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 239000003973 paint Substances 0.000 abstract 1
- 239000009910 sargent gloryvine Substances 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 69
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
- 201000010099 disease Diseases 0.000 description 36
- 210000004696 endometrium Anatomy 0.000 description 26
- 210000003734 kidney Anatomy 0.000 description 20
- 210000004185 liver Anatomy 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 231100000614 poison Toxicity 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 18
- 210000004291 uterus Anatomy 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 230000007812 deficiency Effects 0.000 description 14
- 239000003440 toxic substance Substances 0.000 description 14
- 230000003115 biocidal effect Effects 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- 239000000262 estrogen Substances 0.000 description 13
- 229940011871 estrogen Drugs 0.000 description 13
- 201000000736 Amenorrhea Diseases 0.000 description 12
- 206010001928 Amenorrhoea Diseases 0.000 description 12
- 210000001015 abdomen Anatomy 0.000 description 12
- 231100000540 amenorrhea Toxicity 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000005906 menstruation Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 206010007247 Carbuncle Diseases 0.000 description 10
- 206010013935 Dysmenorrhoea Diseases 0.000 description 10
- 210000001215 vagina Anatomy 0.000 description 10
- 208000005171 Dysmenorrhea Diseases 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 208000006820 Arthralgia Diseases 0.000 description 8
- 208000033809 Suppuration Diseases 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 230000001047 pyretic effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 206010000084 Abdominal pain lower Diseases 0.000 description 7
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Chemical compound COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 description 6
- 208000019255 Menstrual disease Diseases 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- 208000025747 Rheumatic disease Diseases 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 230000002175 menstrual effect Effects 0.000 description 6
- 230000000552 rheumatic effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 201000003453 lung abscess Diseases 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 239000000583 progesterone congener Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 206010000077 Abdominal mass Diseases 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 206010059013 Nocturnal emission Diseases 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 206010048245 Yellow skin Diseases 0.000 description 4
- 206010000210 abortion Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 208000014617 hemorrhoid Diseases 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000002398 materia medica Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 238000000554 physical therapy Methods 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 206010040872 skin infection Diseases 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010063409 Acarodermatitis Diseases 0.000 description 3
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 208000037093 Menstruation Disturbances Diseases 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 201000004458 Myoma Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 208000037062 Polyps Diseases 0.000 description 3
- 241000447727 Scabies Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000024776 abnormal vaginal bleeding Diseases 0.000 description 3
- 201000004171 acute endometritis Diseases 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001839 endoscopy Methods 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000003014 reinforcing effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000005687 scabies Diseases 0.000 description 3
- 230000002522 swelling effect Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 206010051458 Myometritis Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010037714 Quadriplegia Diseases 0.000 description 2
- 208000007893 Salpingitis Diseases 0.000 description 2
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 2
- 208000031737 Tissue Adhesions Diseases 0.000 description 2
- 208000006374 Uterine Cervicitis Diseases 0.000 description 2
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 206010008323 cervicitis Diseases 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 210000003785 decidua Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000007106 menorrhagia Diseases 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 208000010553 multiple abscesses Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 231100000862 numbness Toxicity 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 238000011121 vaginal smear Methods 0.000 description 2
- 239000006216 vaginal suppository Substances 0.000 description 2
- 229940120293 vaginal suppository Drugs 0.000 description 2
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 1
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- 241001290610 Abildgaardia Species 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000118350 Andrographis paniculata Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 244000285790 Cyperus iria Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000117280 Naematelia aurantialba Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241001062472 Stokellia anisodon Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046810 Uterine perforation Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000016018 endometrial polyp Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 239000008738 huangbai Substances 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 230000036445 liquid secretion Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 1
- 210000002097 psoas muscle Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- -1 quick Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 1
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 1
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 206010046811 uterine polyp Diseases 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗慢性子宫内膜炎的中药栓剂,各种原料的重量份数比为:丹参10~20份,三棱10~20份,鸡血藤10~20份,益母草10~20份,败酱草10~20份,红藤10~20份,赤芍10~20份,莪术10~20份,蒲公英10~20份,黄芩10~20份,菟丝子10~20份,青黛10~20份,蛇床子10~20份,覆盆子10~20份,鱼腥草10~20份,白芷10~20份,苦参10~20份,穿心莲10~20份。本发明具有清热利湿、益气消瘀功效、各味用药清补结合、气血同治,可促进气血和调、子宫内膜修复和提高机体免疫力。本发明还具有抑菌、抗炎、镇痛及对血液流变学影响,对子宫内膜炎起到很好的作用,减轻患者痛苦,同时也能显著提高治愈率,减少治愈后的复发。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物原料的医用配制品,特别涉及一种治疗慢性子宫内膜炎的中药栓剂及其制备方法。
背景技术
子宫内膜的慢性发炎叫慢性子宫内膜炎。可由急性子宫内膜炎转变而来;也可由长期的输卵管炎或严重的子宫颈炎扩散而成;宫内节育器、分娩或流产后有少量胎盘残留及胎盘附着部的复旧不全也可导致慢性子宫内膜炎;绝经后的妇女,由于体内雌激素水平降低,子宫内膜与阴道内膜均变得菲薄,容易受细菌的侵袭,发生慢性炎症;另外,子宫粘膜下肌瘤、粘膜息肉也能引起子宫内膜的慢性炎症。
慢性子宫内膜炎的主要症状是不规则月经或子宫出血;下腹痛或坠胀感;白带增多;发烧等;另外,子宫增大,有触痛,子宫旁周围组织增厚压痛。如果老年人患了慢性子宫内膜炎则会出现绝经后再次阴道出血,且有白带增多,变得稀薄、血性。治疗慢性子宫内膜炎时,首先应看有无引起的诱因,如残留胎盘、宫内节育器等。去除这些诱因,慢性子宫内膜炎会很快痊愈。否则,一味消炎、疗效也不会显著。安放的宫内节育器应取出,产后或流产后所致的慢性子宫内膜炎,应作细致的刮宫清除残留的退化胎盘组织;有子宫内膜息肉应摘除;如发现粘膜下子宫肌瘤或子宫内膜癌症应根据情况进行积极治疗;老年性子宫内膜炎,可扩张子宫颈口,以利血液或分泌液流出。
子宫内膜炎急性期,子宫内膜充血,水肿,炎症细胞浸润,重症者出现化脓。急性子宫内膜炎的主要表现为发热,下腹痛,白带增多、有时为血性或有恶臭,有时子宫略大,子宫有触痛。慢性者表现也基本相同,也可有月经过多、下腹痛及腰骶附胀明显。急性子宫内膜炎可进一步发展为子宫肌炎,输卵管炎及盆腔炎,使病情加重。
女性经常会感到下腹隐痛或坠胀感,腰肌部疼痛,白带增多、稀水样、淡黄色或脓性、血性。并且会伴有不规则阴道出血或经期延长、痛经、闭经。子宫呈球形增大、软、有压痛,可有血性、脓性分泌物排出。这就是慢性子宫内膜炎的前兆。约有20%的慢性子宫内膜炎患者可以完全无症状,而是由医生做妇科检查时发现。
子宫内膜炎的主要病因:
一、子宫内膜虽有周期性剥脱,但其基底层并不随之剥脱,一旦基底层有慢性炎症即可长期感染内膜的功能层,导致慢性子宫内膜炎。
二、长期存在的输卵管卵巢炎或严重的宫颈炎可以导致慢性子宫内膜炎。
三、避孕环可引起慢性子宫内膜炎。
四、分娩或流产后有少量胎盘残留或胎盘附着面的愈合不好,常是导致慢性子宫内膜炎的原因。
五、子宫粘膜下肌瘤,粘膜息肉也可导致慢性子宫内膜炎。
六、无明显诱因的慢性子宫内膜炎也可以存在,病原蓖多来自阴道和宫颈。
检查方法
1、病理检查:从病理上分析,内膜间质内有很多浆细胞及淋巴细胞浸润。炎症时间较久者可见纤维母细胞及毛细血管增生。老年性子宫内膜炎呈现血管壁厚、硬化,有时有钙化。病变严重时局部有溃疡形成。内膜腺体萎缩时,表面上皮可有鳞状化生,当鳞状化生广泛时有大片的鳞状上皮覆盖整个子宫腔内壁,称为子宫鱼鳞癣。流产后子宫内膜炎应注意有否绒毛、蜕膜等存在,特别是流产较久,绒毛可高度退化,甚至找不到绒毛,但常在血管的周围可找到散在的片块状蜕膜组织。
2、诊断性刮宫:可明确发病原因及排除恶性病变。术前应控制炎症三天,术后继续给予消炎。术中操作应轻柔,因感染的宫壁脆弱,易致子宫穿孔。老年性子宫内膜炎其内膜菲薄,刮取时更应注意。流产后子宫内膜炎可能残留胚胎组织,应仔细全面刮取进行检查,往往可同时起到治疗作用。
3、实验室检查:可做血及宫腔分泌物细菌培养及药物敏感试验,可明确诊断,且供治疗用药参考。
4、B超的检查:B超进行宫内状态初步诊断,其检查结果结合临床症状及化验结果来诊断手否子宫内膜炎。
西医一般大多数使用抗生素治疗,如青霉素、链霉素、红霉素、庆大霉素等可提高疗效。但一定在医生指导下使用。慢性子宫内膜炎经适当治疗,绝大多数病人可以治愈。一定要树立治愈的信心,坚持治疗;否则,将会半途而废。目前最好的治疗方式是采用中医调理治疗的方法。中医治疗可以有效的解决了疾病的表面症状,又能够彻底的解决致病的根本因素。患者还可以根据具体情况适当的选择物理疗法。但是,患者要注意千万不能随便用药,要在专家的指导下进行。对于物理疗法,也有限度,不能过度,过度反而不利于病情,有损患者的健康。
祖国医学认为该病多由经行产后胞脉空虚,外感湿邪热毒内侵胞宫;或脾肾虚损,水湿内停日久化热;或过食肥甘厚味,内生湿热,下注胞宫;或肝郁气滞化火,痰火流注胞宫,致盆腔脏器内膜气血运行不畅,湿邪热毒、痰火瘀血互结,化腐成脓,损害盆腔组织。由于失治或误治,致反复发作,迁延不愈,器官组织粘连、增生而成瘕包块。该病虚实夹杂、湿热痰瘀相互为患,脾肾虚损是其本,湿热痰瘀阻滞是其标。
子宫内膜炎是妇科常见的多发病,由于其具有病程长、易复发的特点。成为严重危害妇女健康的疾病之一,针对子宫内膜炎的特点,临床治疗主要采用抗炎方法,如口服或静脉滴注抗生素,同时配合阴道冲洗上药等措施,后期人们发现子宫内膜炎还与体内雌激素分泌减少有关,体内雌激素水平降低会使子宫内膜变薄。更容易受到致病菌侵袭而引起炎症;故又加入了口服雌孕激素来改善子宫内膜功能,但临床治疗效果仍得不到较大改善,许多研究者期望通过中医药来解决问题。
发明内容
本发明所要解决的技术问题在于,西医对于本症一般大多数使用抗生素治疗,如青霉素、链霉素、红霉素、庆大霉素等,容易反复。目前最好的治疗方式是采用中医调理治疗的方法。中医治疗可以有效的解决了疾病的表面症状,又能够彻底的解决致病的根本因素。患者还可以根据具体情况适当的选择物理疗法。但是,中医讲究对症下药,个体差异明显,要在专家的指导下进行。对于物理疗法,也有限度,不能过度,过度反而不利于病情,有损患者的健康。本发明在传统医学的基础上结合多年临床经验,采用现代加工方法精心研制而成。本发明对原料药品的各有效成分科学配伍,能直达病灶,且见效快、副作用小、抑菌性强的制剂,能有效解除患者的痛苦,达到祛除疾病的目的。
为解决上述技术问题,本发明提供了一种治疗慢性子宫内膜炎的中药栓剂,其所述中药栓剂中各种原料的重量份数比可以为:丹参10~20份,三棱10~20份,鸡血藤10~20份,益母草10~20份,败酱草10~20份,红藤10~20份,赤芍10~20份,莪术10~20份,蒲公英10~20份,黄芩10~20份,菟丝子10~20份,青黛10~20份,蛇床子10~20份,覆盆子10~20份,鱼腥草10~20份,白芷10~20份,苦参10~20份,穿心莲10~20份。
所述治疗慢性子宫内膜炎的中药栓剂,其所述中药栓剂中各种原料的重量份数比还可以为:丹参10~15份,三棱10~15份,鸡血藤10~15份,益母草10~15份,败酱草10~15份,红藤10~15份,赤芍10~15份,莪术10~15份,蒲公英10~15份,黄芩10~20份,菟丝子10~20份,青黛10~20份,蛇床子10~20份,覆盆子10~20份,鱼腥草10~20份,白芷10~20份,苦参10~20份,穿心莲10~20份。
所述治疗慢性子宫内膜炎的中药栓剂,其所述中药栓剂中各种原料的重量份数比也可以为:丹参10~20份,三棱10~20份,鸡血藤10~20份,益母草10~20份,败酱草10~20份,红藤10~20份,赤芍10~20份,莪术10~20份,蒲公英10~20份,黄芩10~15份,菟丝子10~15份,青黛10~15份,蛇床子10~15份,覆盆子10~15份,鱼腥草10~15份,白芷10~15份,苦参10~15份,穿心莲10~15份。
为解决上述技术问题,本发明还提供一种治疗慢性子宫内膜炎的中药栓剂的制备方法,其所述栓剂的制备步骤包括:将所述原料药除白芷与青黛外,其余加水浸泡30分钟至1小时,加热煮沸30~40分钟,过滤,滤液备用;滤渣加水,第二次加热,煮沸30~40分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸30~40分钟,过滤;将三次滤液合在一起,加热浓缩至膏状,再将白芷、青黛用水蒸汽蒸馏法提取,得结晶物,混在上述得到的药膏里;选取基质50℃~60℃加热融化,加入上述得到的药膏冷却定型制成类弹头状栓剂,紫外线杀毒。
所述治疗慢性子宫内膜炎的中药栓剂的制备方法,其所述栓剂所用的基质可以选自:半合成脂肪酸甘油酯、泊洛沙姆、聚乙二醇、羊毛脂中的一种或多种;所述基质在温度50℃~60℃条件下加热融化,加入所述制备方法制得的药物膏体,水浴搅拌均匀,混合成粘稠的液体,灌注在塑料定型管内,插入棉栓,冷却定型制成子弹头状栓剂;所述棉栓为尾部带有棉线的棉栓。
为解决上述技术问题,本发明再提供一种治疗慢性子宫内膜炎的中药栓剂的制备方法,所述栓剂的制备过程进一步包括:
a.将所述原料药除白芷和青黛外放入粉碎机粉碎后过筛,
b.将过筛后剩下的颗粒物放入乙醇中加热回流提取2次;
c.再取上述乙醇提取后的药渣,加水加热回流提取2次;
d.将青黛与白芷蒸馏汽化得结晶,加入上述两种提取液中,基质调和罐装定型,紫外线杀毒。
所述步骤a中,可以将所述原料药除白芷与青黛外放入粉碎机粉碎后过100-120目细筛,使能通过细筛的细粉量在达到30%,收集通过细筛的原料细粉备用。
所述步骤b中,可以将过筛后剩下的颗粒物放入乙醇中加热回流提取2次,每次1~2小时,将2次提取液合并静置;
所述步骤c中,可以将上述乙醇提取过的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置。
所述步骤d中,可以将青黛与白芷蒸馏汽化得结晶,干燥成粉末;再将上述两种提取液合并,减压浓缩相对密度为80℃时1.37的滤液,回收乙醇,将所得滤液调整比重到1.06,加入过筛的细粉和结晶粉末后搅匀,倒入基质中,50℃~60℃加热融化,冷却定型制成类弹头状栓剂,所述粉剂中成药与基质的配比为1∶2~1∶4;所述棉栓为尾部带有棉线的棉栓。
本发明采用药栓和棉栓一体工艺,弥补了普通栓剂的不足,普通栓剂不能有效送达到阴道的深处。由于阴道的自净作用,当有异物存在时,会增加液体分泌,在短时间内将药物排除体外,既降低了疗效,又延长了疗程,增加费用又污染内衣裤。而本发明克服这一技术难题,制成的栓剂可充分发挥药物疗效,具有安全性好,可行性好的优点,能直达病灶,达到祛病目的。
本发明具有清热利湿、益气消瘀功效,用于治疗湿热阻滞导致的下腹痛、白带增多与色黄质稠、腰骶酸痛及神疲乏力等症状;本发明中含有穿心莲、败酱草和鱼腥草等中药,菟丝子有固精涩肠作用,穿心莲有清热凉血、解毒消肿功效,蛇床子具有利湿祛风、消散瘀血功效;本发明各味用药清补结合、气血同治,最终达到促进气血和调、子宫内膜修复和提高机体免疫力的目的。研究也发现,本发明还具有抑菌、抗炎、镇痛及对血液流变学影响,这些功能均能对子宫内膜炎起到很好的作用,从而与抗生素形成良好的协同作用;临床中将两药联用能及时控制临床症状,减轻患者痛苦,同时也能显著提高治愈率,减少治愈后的复发。
具体实施方式
子宫内膜炎的治疗,首先当辨别寒热与虚实,属热属实者,急当清热解毒、利湿止带、化瘀止痛,以防病势深入;属寒属虚者,当以温肾助阳、散寒除湿、化瘀止痛之法,以利扶正祛邪,在具体疗法上,可选用内服汤剂、外敷、针刺、灌肠等法,根据不同的病情配合应用,常用治法如。
子宫内膜炎是妇科常见的多发病,由于其具有病程长、易复发的特点。成为严重危害妇女健康的疾病之一,针对子宫内膜炎的特点,临床治疗主要采用抗炎方法,如口服或静脉滴注抗生素,同时配合阴道冲洗上药等措施,后期人们发现子宫内膜炎还与体内雌激素分泌减少有关,体内雌激素水平降低会使子宫内膜变薄。更容易受到致病菌侵袭而引起炎症;故又加入了口服雌孕激素来改善子宫内膜功能,但临床治疗效果仍得不到较大改善,许多研究者期望通过中医药来解决问题。
中医认为子宫内膜炎是由于热毒壅盛、湿热阻滞及寒湿凝滞所致,而本发明正具有清热利湿、益气消瘀功效,用于治疗湿热阻滞导致的下腹痛、白带增多与色黄质稠、腰骶酸痛及神疲乏力等症状;本发明中含有穿心莲、败酱草和鱼腥草等八味中药,菟丝子有固精涩肠作用,穿心莲有清热凉血、解毒消肿功效,蛇床子具有利湿祛风、消散瘀血功效;本发明各味用药清补结合、气血同治,最终达到促进气血和调、子宫内膜修复和提高机体免疫力的目的。研究也发现,本发明还具有抑菌、抗炎、镇痛及对血液流变学影响,这些功能均能对子宫内膜炎起到很好的作用,从而与抗生素形成良好的协同作用;临床中将两药联用能及时控制临床症状,减轻患者痛苦,同时也能显著提高治愈率,减少治愈后的复发。
祖国医学认为该病多由经行产后胞脉空虚,外感湿邪热毒内侵胞宫;或脾肾虚损,水湿内停日久化热;或过食肥甘厚味,内生湿热,下注胞宫;或肝郁气滞化火,痰火流注胞宫,致盆腔脏器内膜气血运行不畅,湿邪热毒、痰火瘀血互结,化腐成脓,损害盆腔组织。由于失治或误治,致反复发作,迁延不愈,器官组织粘连、增生而成瘕包块。该病虚实夹杂、湿热痰瘀相互为患,脾肾虚损是其本,湿热痰瘀阻滞是其标。
本发明的目的,就是针对妇科疾病中盆腔炎的药物的疗效均不理想,见效较慢,对人体副作用大,对妇女身体危害较大,且易反复的缺点,发明生产一种见效快、副作用小、抑菌性强的药物,以解除患者的痛苦。本发明继承祖国的医学遗产,将中华医药发扬光大,利用满山遍野的中草药资源优势,研制一种特效、安全、方便、价廉、纯天然的中药制剂,用以治疗妇女的各种盆腔炎等常见妇科病,多发病,弥补西药毒副作用大,对妇女身体危害深等缺陷。本发明制备工艺简单,药物原料价格低廉,疗效好,能达到比较好的社会效果及经济利益。本发明具有活血化瘀、清利湿热的功效,用于气滞蕴结之盆腔炎,症见带下量多,下腹疼痛等症,同时适用于慢性盆腔炎、慢性附件炎、卵巢囊肿、阴道炎等常见病的治疗,效果显著。该药具有溶解快、释药迅速的优点,达到快速缓解症状和治疗的目的。
丹参苦,微寒。归心、肝经。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠。用于胸肋胁痛,风湿痹痛,症瘕结块,疮疡肿痛,跌仆伤痛,月经不调,经闭痛经,产后瘀痛等。治疗胸肋疼痛、症瘕结块,以及月经不调、经闭经痛具有良效。《纲目》载:丹参,按《妇人明理论》云,四物汤治妇人病,不问产前产后,经水多少,皆可通用,惟一味丹参散,主治与之相同。盖丹参能破宿血,补新血,安生胎,落死胎,止崩中滞下,调经脉。
赤芍味苦,微寒。归肝经。功能主治清热凉血,散瘀止痛。用于温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,症瘕腹痛,跌扑损伤,痈肿疮疡。赤芍能清血分实热,散瘀血留滞。本品功能与丹皮相近,故常与丹皮相须为用。但丹皮清热凉血的作用较佳,既能清血分实热,又能治阴虚发热;而赤芍只能用于血分实热,以活血散瘀见长。
鸡血藤性苦、甘,温。归肝、肾经,补血,活血,通络。用于月经不调,血虚萎黄,麻木瘫痪,风湿痹痛活血舒筋;养血调经,《本草纲目拾遗》载其能医手足麻木;肢体瘫痪;风湿痹痛;妇女有经不调;痛经。
败酱草性味苦平,具有清热解毒、排脓破瘀的功效。能医肠痈、下痢、赤白带下、产后瘀滞腹痛、目赤肿痛。入胃、大肠、肝经。主治清热解毒,消痈排脓,活血行瘀。用于肠痈、肺痈及疮痈肿毒,实热瘀滞所致的胸腹疼痛,产后瘀滞腹痛等症。
蛇床子性辛、苦,温;有小毒。归肾经。主治温肾壮阳,燥湿,祛风,杀虫。用于阳痿,宫冷,寒湿带下,湿痹腰痛;外治外阴湿疹,妇人阴痒;滴虫性阴道炎,是妇科外用良药。《本草经疏》载:蛇床子,味苦平;《别录》辛甘无毒;今详其气味,当必兼温燥,阳也。故主妇人阴中肿痛,男子阴痿湿痒,除痹气,利关节,恶疮。《别录》温中下气,令妇人子服热,男子阴强,令人有子。盖以舌能除湿,温能散寒,辛能润肾,甘能益脾,故能除妇人男子一切虚寒湿所生病。寒湿既除,则病去,性能益阳,故能已疾,而又有补益也。
青黛具有清热,凉血,解毒的功效,且性甘,平,无毒,入肝、肺、胃经。清热解毒,凉血,定惊,用于温毒发斑,血热吐衄,胸痛咳血,口疮,痄腮,据《要药分剂》载:除热解毒,兼能凉血。《雷公炮制药性解》载:“入肝,脾二经。”
蒲公英是一味常用的中药,其药用价值早已载入各种医书。它全草入药,含蒲公英甾醇、蒲公英赛醇、蒲公英苦素、咖啡酸、胆碱、菊糖等成分。性平味甘微苦。可清热解毒,消肿散结。《本草纲目》记载:“解食毒,散滞气,清热毒,化食毒,消恶肿、结核、疔肿。”蒲公英昧甘平,其性无毒。当是入肝入胃,解热凉血之要药。
穿心莲为爵床科植物穿心莲(Andrographis paniculata(Burm.f.)Nees)的全草或叶。又名春莲秋柳,一见喜,榄核莲、苦胆草、金香草、金耳钩、印度草,苦草等。味苦,性寒。归心、肺、大肠、膀胱经。有清热解毒、消炎、消肿止痛作用。主治细菌性痢疾、尿路感染、急性扁桃体炎、肠炎、咽喉炎、肺炎和流行性感冒等,外用可治疗疮疖肿毒、外伤感染等。《广西中草药》:止血凉血,拔毒生肌,治肺脓疡,口腔炎。
鸡血藤性苦、甘,温。归肝、肾经,补血,活血,通络。用于月经不调,血虚萎黄,麻木瘫痪,风湿痹痛活血舒筋;养血调经,《本草纲目拾遗》载其能医手足麻木;肢体瘫痪;风湿痹痛;妇女有经不调;痛经。外用是活血化淤的妇科良药。
红藤根茎可药用,有通经活络、散瘀止痛、理气行血、杀虫等功效,主治风湿痛、跌打损伤、痛经、闭经、蛔虫。苦,平。归大肠、肝经。功能与主治:清热解毒,活血,祛风止痛。用于肠痈腹痛,热毒疮疡,经闭,痛经,跌扑肿痛,风湿痹痛。抑菌作用用平碟法试验,25%煎剂对金黄色葡萄球菌、乙型链球菌有极敏感抑菌作用,对大肠杆菌、绿脓杆菌、甲型链球菌、卡他球菌、白色葡萄球菌均有高敏感抑菌作用。
覆盆子植物可入药,有多种药物价值,其果实有补肾壮阳的作用。覆盆子油属于不饱和脂肪酸,可促进前列腺分泌苛尔蒙。功效:补肝益肾,固精缩尿,明目。以大鼠、兔的阴道涂片及内膜切片作治疗指标,覆盆子似有雌激素样作用。抑菌作用100%煎剂用平板打洞法,对葡萄球菌有抑制作用,对霍乱弧菌也有抑制作用。雌激素样作用大鼠、兔的阴道涂片及内膜切片等指标表明,覆盆子似有雌激素样作用。
益母草味辛苦、凉。活血、祛淤、调经、消水。治疗妇女月经不调,胎漏难产,胞衣不下,产后血晕,瘀血腹痛,崩中漏下,尿血、泻血,痈肿疮疡。益母草碱性皮下注射有中枢抑制作用,MLD为0.4-0.6g/kg。兔静脉注射益母草碱1mg/kg,可见尿量显著增加。益母草碱在较高浓度时能使兔血悬液发生溶血作用。益母草碱水浸液用试管稀释法1∶13-1∶10,对许兰氏毛菌,羊毛样小孢子菌、红色表皮癣菌、星状奴卡氏菌均有抑制作用。益母草煎剂用平板纸片法,对大肠杆菌、志贺氏痢疾杆菌有抑制作用。益母草能去淤生新,活血调经,含有硒、锰等多种微量元素,能抗氧化、防衰老,具有相当不错的益颜美容、抗衰防老功效。
黄芩有清热燥湿,凉血安胎,解毒功效。主治温热病、上呼吸道感染、肺热咳嗽、湿热黄胆、肺炎、痢疾、咳血、目赤、胎动不安、高血压、痈肿疖疮等症。黄芩的临床应用抗菌比黄连还好,而且不产生抗药性。我们借助广谱抗菌作用强的特点,用在真菌培养杂菌感染特厉害,用黄芩提取液效果很好。《本草经疏》:黄芩,其性清肃,所以除邪:味苦所以燥湿;阴寒所以胜热,故主诸热。诸热者,邪热与遍热也,黄疸、肠僻、泄痢,皆湿热胜之病也,析其本,则诸病自瘳矣。
白芷性味归经:辛,温。归肺、胃经。祛风散寒,通窍止痛,消肿排脓,燥湿止带。《日华子本草》:治目赤胬肉,及补胎漏滑落,破宿血,补新血,乳痈、发背、瘰疬、肠风、痔瘘,排脓,疮痍、疥癣,止痛生肌,去面皯疵瘢。
苦参性苦,寒。归心、肝、胃、大肠、膀胱经清热燥湿,杀虫,利尿。用于热痢,便血,黄疸尿闭,赤白带下,阴肿阴痒,湿疹,湿疮,皮肤瘙痒,疥癣麻风;外治霉菌性阴道炎,常与黄柏结合使用,是治疗阴道炎的外用妇科良药。
菟丝子在《神农本草经》中被列为上品。其气味辛,甘,平无毒。功能与主治:补肾益精,养肝明目。适用于肝肾不足的腰膝筋骨酸痛,腿脚软弱无力、阳痿遗精、呓语、小便频数、尿有佘沥、头晕眼花、视物不清、耳鸣耳聋以及妇女带下、习惯性流产等症。一般情况下被列为上品的可以久服,久服明目轻身延年。但阳虚火旺、阳强不痿及大便燥结者禁服,根据个人体质,如果出现上火迹象,就停止服用。它会引起性功能亢进。《本经逢原》:″菟丝子,祛风明目,肝肾气分也。其性味辛温质粘,与杜仲之壮筋暖腰膝无异。其功专于益精髓,坚筋骨,止遗泄,主茎寒精出,溺有佘沥,去膝胫酸软,老人肝肾气虚,腰痛膝冷,合补骨脂、杜仲用之,诸筋膜皆属于肝也。气虚瞳子无神者,以麦门冬佐之,蜜丸服,效。凡阳强不痿,大便燥结,小水赤涩者勿用,以其性偏助阳也。″针对都市上班族普遍使用电脑办公久视,烟酒无度,夜生活不节制、过度用眼总得不到缓解等伤害肝脏的行为,采用日常饮用,能补虚益精气,祛风明目,滋补肝肾,起到良好的保健作用。
三棱:又名带皮三棱。为莎草科植物荆三棱Scirpusflaviatilis(Torr.)A.Gray的块根。以上均以质坚、体重、干燥、去净外皮、表面黄白色者为佳。治症瘕积聚、气血凝滞、心腹疼痛、胁下胀疼、经闭、产后瘀血腹痛、跌打损伤、疮肿坚硬。《日华子本草》:治妇人血脉不调,心腹痛,落胎,消恶血,补劳,通月经,治气胀,消扑损瘀血,产后腹痛、血运并宿血不下。《开宝本草》:主老癖症瘕结块。
莪术辛、苦,温。归肝、脾经。行气破血,消积止痛。用于燀瘕痞块,瘀血经闭,食积胀痛;早期宫颈癌。功效主治:破血行气止痛:本品功效与三棱相似,但温通力较大,可治疗血滞经闭腹痛、腹部包块、积聚。积散结:本品能行气消积止痛,用于饮食积滞、胸腹满闷作痛。破血祛瘀,妇女闭经,或痰湿淤血凝结而成的症瘕癖块。贾所学:“蓬术味辛性烈,专攻气中之血,主破积消坚,去积聚癖块,经闭血瘀,扑报疼痛。与三棱功用颇同,亦勿过服。”(《药品化义》)
鱼腥草性微寒,味苦。归肺经、膀胱、大肠经。清热解毒;排脓消痈;利尿通淋。主治:热淋主肺痈吐脓;痰热喘咳;喉哦;热痢;痈肿疮毒;热淋。功效:清热解毒,利尿消肿。治肺炎,肺脓疡,热痢,疟疾,水肿,淋病,白带,痈肿,痔疮,脱肛,湿疹,秃疮,疥癣。《滇南本草》:治肺痈咳嗽带脓血,痰有腥臭,大肠热毒,疗痔疮。《纲目》:散热毒痈肿,疮痔脱肛,断痁疾,解硇毒。《医林纂要》:行水,攻坚,去瘴,解暑。疗蛇虫毒,治脚气,溃痈疽,去瘀血。
本发明栓剂的制备步骤为:取丹参1500g,三棱1500g,鸡血藤1500g,益母草1500g,败酱草1500g,红藤1500g,赤芍1500g,莪术1500g,蒲公英1500g,黄芩1500g,菟丝子1500g,蛇床子1500g,覆盆子1500g,鱼腥草1500g,苦参1500g,穿心莲1500g,加水浸泡30分钟至1小时,加热煮沸30~40分钟,过滤,滤液备用;滤渣加水,第二次加热,煮沸30~40分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸30~40分钟,过滤;将三次滤液合在一起,加热浓缩至膏状,再将白芷1500g、青黛1500g用水蒸汽蒸馏法提取,得结晶物,混在上述得到的药膏里;选取基质50℃~60℃加热融化,加入上述得到的药膏冷却定型制成类弹头状栓剂,紫外线杀毒。所述栓剂所用的基质选自:半合成脂肪酸甘油酯、泊洛沙姆、聚乙二醇、羊毛脂中的一种或多种;所述基质在温度50℃~60℃条件下加热融化,加入所述制备方法制得的药物膏体,水浴搅拌均匀,混合成粘稠的液体,灌注在塑料定型管内,插入棉栓,冷却定型制成子弹头状栓剂;所述棉栓为尾部带有棉线的棉栓。
本发明栓剂的制备步骤还可以为:取丹参1200g,三棱1300g,鸡血藤1200g,益母草1200g,败酱草1200g,红藤1100g,赤芍1200g,莪术1200g,蒲公英1200g,黄芩1200g,菟丝子1100g,蛇床子1100g,覆盆子1200g,鱼腥草1200g,苦参1200g,穿心莲1200g,将所述原料药,放入粉碎机粉碎后过100-120目细筛,使能通过细筛的细粉量在达到30%,收集通过细筛的原料细粉备用。将过筛后剩下的颗粒物放入乙醇中加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述乙醇提取过的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置。将青黛1200g与白芷1200g蒸馏汽化得结晶,干燥成粉末;再将上述两种提取液合并,减压浓缩相对密度为80℃时1.37的滤液,回收乙醇,将所得滤液调整比重到1.06,加入过筛的细粉和结晶粉末后搅匀,倒入基质中,50℃~60℃加热融化,冷却定型制成类弹头状栓剂,所述粉剂中成药与基质的配比为1∶2~1∶4;所述棉栓为尾部带有棉线的棉栓。
本发明治疗慢性子宫内膜炎中药制剂,药剂制成栓剂,则取基质加热融化,温度50℃~60℃,加入本发明的药细粉,水浴搅拌均匀,混合成粘稠的液体,灌注在塑料定型管内,插入棉栓,冷却定型制成类似子弹头状栓剂。一般所用基质可为:半合成脂肪酸甘油酯、羊毛脂、聚乙二醇,药细粉与基质的配比为1∶2~1∶4,优选为1∶3,或采用泊洛沙姆poloxamer作为基质,其已被广泛用作栓剂的亲水性基质,具有以下优点:比其他基质的溶解度柔和、快速,载药量也较高。
所述栓剂的具体用法如下:将本发明药物栓剂除去塑料外壳,取出药栓,拉出尾部棉线,将药栓纳入阴道底部,每晚一次,棉线留在体外,次日晨起拉出棉栓,连续用药7天为一疗程。
毒理学试验:
试验例1:本发明急性毒性试验
一、试验材料:
动物:昆明种小鼠,体重21-24g,雌雄各半,山东大学生物试验室育种。药物:本发明栓剂。
二、方法:
1、LD50计算:采用改良寇氏法,将小鼠随机分成5组,每组10只,雌雄各半,将栓剂溶解,配成最大浓度,按小鼠最大允许容量给药,所给剂量按生药量依次为18,14.4,11.5,9.2,7.4(g.kg-1),在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml,治疗动物死亡情况。
2、最大耐受剂量测定(MTD值):取小鼠20只,雌雄各10只。将栓剂加蒸馏水溶解,配成最高浓度,按动物的最大耐受量,以注射灌喂器能抽动为准。在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml(每ml含生药0.36g),总药量为18g生药/kg.d,相当临床成人50Kg体重用量的300倍。给药后连续治疗7天。
三、试验结果:
在LD50计算中当用最大允许浓度和最大允许容量给予小鼠时(18g/Kg.d),未见小鼠死亡,即未测出LD50,只可求最大耐受剂量,在7天治疗期中,动物其食欲、活动、毛色、精神状态等皆正常,发育正常,未见有死亡。即选用相当于临床剂量的300倍药量,并无不良反应发生,表明急性毒性极小,MTD>18g/Kg.d。
试验例2:本发明急性皮肤刺激试验报告
1、实验目的:检测栓剂对实验动物皮肤的刺激/腐蚀作用和强度
2、材料和方法:
2.1.受试物:名称:本发明洗栓剂(实施例2方法制得)
2.2.实验动物:壹级大耳白种家兔,10只,雌性,体重2.1-2.3kg;由青岛大学医学院生物系实验动物中心提供;
2.3.试验万法:
选用皮肤完好的健康家兔10只,于试验前24小时将其背部脊柱两侧被毛剪掉,去毛面积左、右各约4cm×4cm。试验时取受试物0.2ml涂于2.5cm×2.5cm的二层纱布上,敷贴于一侧去毛皮肤表面,油纸覆盖,胶布固定。另一侧皮肤作为空白对照。封闭4小时后,去除覆盖物,并用温水清洗去残留受试物,于去除受试物后的1、24和48小时治疗涂抹部位皮肤反应,并评分。
3、实验结果:实验动物皮肤未出现任何红斑,红肿,发炎现象。
4、小结:根据《消毒技术规范》(1999)中皮肤刺激反应评分标准判定,本发明软膏剂对动物皮肤刺激强度属无刺激性。
实施例3:阴道粘膜刺激试验结果
1.试验方法:
实验动物检疫3天后,选用18只上述健康家兔,随机分为三组,每组各6只,分别为:空白对照、赋形剂对照、本发明栓剂组(按应用液5倍浓度)。分别用适当大小的灭菌棉条浸以灭菌生理盐水和受试物置于赋形剂对照组和受试物组动物阴道内,与阴道粘膜接触6小时,24小时后处死动物。取出局部阴道组织,治疗病变情况。
2、试验结果:阴道粘膜刺激试验结果
实施例4:皮肤过敏试验结果
用本发明栓剂,进行诱导和激发接触试验,在24小时和48小时后治疗试验小鼠,均不见皮肤有红斑及水肿等现象,与阴性对照组无差异。结果表明,该栓剂对皮肤反应强度近于零,即无皮肤变态反应。
实施例5:长期毒性实验资料
1、实验方法
将豚鼠随机份成4组,每组15只。在豚鼠背部脊柱两侧将脱毛剂均匀涂上,使其脱毛范围约40平方厘米。洗净脱毛剂,治疗24小时后每组豚鼠分别涂本发明栓剂溶液0.2、0.4和0.8ml,分别含生药92、184和368mg,另一组涂溶媒0.8ml每日二次,连续30天,治疗豚鼠的一般情况,实验结束后处死动物进行血液学、血液生化及病理学检查。
2、结果
上述三组用药豚鼠躯干去毛区,未见局部皮肤有水肿、充血、红斑、出血点及溃疡。用药组与对照组动物毛发色泽、摄食、四肢活动等对照组无明显差异,血液生化检查,用药组与对照组均在正常范围。病理组织学检查,实验各组心、肝、肾及局部皮肤均未见明显病变。提示,本发明中药栓剂长期用药对局部皮肤及全身重要脏器均未见明显的毒性作用。
试验结果表明:本发明中药栓剂实验安全。该药对乙型链球菌、金黄色葡萄球菌、大肠杆菌的最小抑制浓度为1∶150,淋球菌为1∶150,白色念珠菌为1∶300,对1∶20稀释度时的杀灭时间为5分钟,1∶50时为10分钟,1∶100时为20分钟,1∶200时为40分钟,1∶400时为8小时。
临床试验:
在女性生殖系统感染疾病中,子宫内膜炎是常见疾病。病情如果不能得到有效控制,将可能影响子宫肌层发展成为子宫肌炎,引发子宫内膜炎原因众多,常见致病原因有流产、安放避孕器、月经期性交、体内雌激素下降及阴道内酸度降低等,以上均会诱发子宫内膜炎。临床上治疗子宫内膜炎常予以口服抗生素和人工周期雌孕激素,同时配合阴道冲洗上药,近年来这种传统疗法受到质疑。源于以上疗法还处于对症治疗阶段,所以临床病例经治疗后复发率高、预后情况不佳。
本文在传统疗法的基础上使用阴道栓剂治疗。期望患者经治疗后,既能有效控制子宫内膜炎的临床症状,也能促进子宫内膜修复、提高机体免疫力,从而达到标本兼治的目的。
1资料与方法
1.1治疗组临床资料2010年3月-2012年3月我院共收治160例子宫内膜炎患者,将其随机分为治疗组和对照组,每组80例。治疗组年龄22~38岁,平均31.4±2.2岁,病程4~35周。平均22.3±1.9周;子宫内膜厚度3.2±0.5mm;月经不规则患者68例,占总数87.2%,月经量减少患者59例,占总数75.6%,阴道不规则出血患者53例,占总数67.9%;白带或分泌物增多患者72例,占总数92.3%,下腹部坠痛患者64例,占总数82.1%,行阴道内镜检查子宫内膜充血粘连患者76例,行B超检查显炎性反应图像患者67例(见表1)。
1.2对照组临床资料对照组年龄25~37岁,平均31.7±1.8岁。病程4~35周,平均2O.7±2.2周;子宫内膜厚度3.6±0.4mm,月经不规则患者62例,占总数79.5%,月经量减少患者56例,占总数71.8%,阴道不规则出血患者51例,占总数65.4%;白带或分泌物增多患者69例,占总数88.5%,衰1两组患者临床资料比较下腹部坠痛患者61例,占总数78.2%,行阴道内镜检查子宫内膜充血粘连患者73例,行B超检查显炎性反应图像患者62例。
1.3治疗方法对照组患者口服广谱抗生素和雌孕激素炔诺酮,同时配合阴道冲洗上药,治疗周期6周;治疗组患者在使用阴道栓剂,治疗周期6周;两组患者治疗结束后治疗子宫内膜厚度、月经情况等,判断治疗效果优劣。
1.4疗效判断参考(妇产科学>将治疗效果分为三类:痊愈即月经情况恢复正常,下腹部坠痛症状消失,白带或分泌物增多症状消失,阴道内镜检查子宫内膜充血粘连症状消失子宫内膜适当增厚。B超检查炎症反应图像消失;有效即月经恢复情况较好,下腹部坠痛感消失或不明显,白带或分泌物减少,子宫内膜厚度适当增加及充血粘连症状正转好;无效即以上体征无变化或变化不明显,少数患者临床症状甚至恶化。总有效率=[(痊愈+有效)病例数/总病例数]×100%。
1.5统计学分析将所有患者的资料建立数据库。采用SPSS 16.0统计学软件对所有资料进行检验分析,数据表达采用x±S方式,P<0.05差异有统计学意义。
2结果
2.1临床资料分析影响患者治疗效果的因素众多。如患者就诊前子宫内膜厚度、月经情况、内膜充血粘连情况及白带或分泌物情况等,两组基本资料对比,资料差异无统计学意义,两组患者来自同一属性总体。
2.2治疗效果分析两组患者经不同方法治疗后,治疗组患者子宫内膜厚度5.15±0.62mm,经期恢复正常患者72例,月经量恢复正常患者74例,阴道不规则出血患者7例;白带或分泌物增多患者8例。下腹部坠痛患者9例,子宫内膜充血粘连患者6例,B超检查炎性反应图像患者3例,痊愈率;对照组以上治疗指标明显低于治疗组,两组行不同疗法的治疗效果差异有统计学意义(见表1、2)。
2.3协同作用治疗结果通过对比治疗效果发现,治疗组治疗后分泌物仍然增多患者8例,占总数10%,对照组分泌物增多患者29例,占总数36.25%;治疗组治疗后内膜充血粘连6例,占总数7.5%,对照组21例,占总数26.25%;治疗组月经情况恢复正常者也优于对照组。治疗组加服本发明后在以上三方面与对照组差异显著,这得益于本发明能促进子宫内膜修复和减轻内膜充血粘连,同时该药还能提高机体免疫力。增强人体自身抵抗病菌侵袭能力,弥补了单纯抗生素治疗在这些方面的不足,两者联用能产生很好的协同作用运用于临床能明显改善临床症状和提高疗效。
表2 两组治疗后月经情况对比(n,%)
注:x2=10.389,P=0.014
表3 两组其它疗效判断指标比较(n,%)
注:x2=10.881,P=0.012
3讨论
子宫内膜炎是妇科常见的多发病,由于其具有病程长、易复发的特点。成为严重危害妇女健康的疾病之一,针对子宫内膜炎的特点,临床治疗主要采用抗炎方法,如口服或静脉滴注抗生素,同时配合阴道冲洗上药等措施,后期人们发现子宫内膜炎还与体内雌激素分泌减少有关,体内雌激素水平降低会使子宫内膜变薄。更容易受到致病菌侵袭而引起炎症;故又加入了口服雌孕激素来改善子宫内膜功能,但临床治疗效果仍得不到较大改善,许多研究者期望通过中医药来解决问题。
中医认为子宫内膜炎是由于热毒壅盛、湿热阻滞及寒湿凝滞所致,而本发明正具有清热利湿、益气消瘀功效,用于治疗湿热阻滞导致的下腹痛、白带增多与色黄质稠、腰骶酸痛及神疲乏力等症状;本发明中含有穿心莲、败酱草和鱼腥草等八味中药,菟丝子有固精涩肠作用,穿心莲有清热凉血、解毒消肿功效,蛇床子具有利湿祛风、消散瘀血功效;本发明各味用药清补结合、气血同治,最终达到促进气血和调、子宫内膜修复和提高机体免疫力的目的。研究也发现,本发明还具有抑菌、抗炎、镇痛及对血液流变学影响,这些功能均能对子宫内膜炎起到很好的作用,从而与抗生素形成良好的协同作用;临床中将两药联用能及时控制临床症状,减轻患者痛苦,同时也能显著提高治愈率,减少治愈后的复发。
综上所述,本文将本发明联用抗生素用于治疗子宫内膜炎,临床中取得满意疗效,通过分析本发明的组方和功效,发现两药联用能产生良好协同作用,虽然两药作用机理不同,但都对子宫内膜炎的致病原因起到较强抑制作用,既能及时有效控制临床症状,也能提高治疗效果和减少复发率。
具体实施例:钱某,27岁,患者以前有人流史,带下痛经两年佘。刮宫不彻底。近1年来黄白带下严重,味腥臭,腰腹坠痛,月事错前,色黯质浓,10d方干净,经前感觉会阴及腹部胀痛,状如临盆,苦涩不堪,须用止痛片方能缓解。患者有下腹痛、白带增多与色黄质稠、腰骶酸痛及神疲乏力等症状。患者舌红、苔薄黄,脉细数弦。妇科检查:慢性子宫内膜炎,阴道充血,宫颈下唇中糜,附件右侧增厚压痛,宫体大小正常,白带镜检:红血球(+),脓球(+++),证属湿浊之邪久滞带脉,瘀热互结成为带下,治宜燥湿,清热,利湿。使用如下配方:丹参12g,三棱13g,鸡血藤11g,益母草12g,败酱草11g,红藤13g,赤芍12g,莪术12g,蒲公英11g,黄芩12g,菟丝子13g,青黛13g,蛇床子12g,覆盆子11g,鱼腥草12g,白芷13g,苦参12g,穿心莲11g,制成栓剂。在月经期后,将本发明药物栓剂除去塑料外壳,取出药栓,拉出尾部棉线,将药栓纳入阴道深部,棉线留在体外,每晚1粒,次日晨起拉出棉栓,连续用药7天为一疗程。连用4个疗程。4个疗程见效。渐觉带下减少,色转浅淡,腰腹坠痛明显减轻,再使用本中药制剂3疗程渐愈。
Claims (10)
1.一种治疗慢性子宫内膜炎的中药栓剂,其特征在于,所述中药栓剂中各种原料的重量份数包括:丹参10~20份,三棱10~20份,鸡血藤10~20份,益母草10~20份,败酱草10~20份,红藤10~20份,赤芍10~20份,莪术10~20份,蒲公英10~20份,黄芩10~20份,菟丝子10~20份,青黛10~20份,蛇床子10~20份,覆盆子10~20份,鱼腥草10~20份,白芷10~20份,苦参10~20份,穿心莲10~20份。
2.根据权利要求1所述治疗慢性子宫内膜炎的中药栓剂,其特征在于,所述中药栓剂中各种原料的重量份数包括:丹参10~15份,三棱10~15份,鸡血藤10~15份,益母草10~15份,败酱草10~15份,红藤10~15份,赤芍10~15份,莪术10~15份,蒲公英10~15份,黄芩10~20份,菟丝子10~20份,青黛10~20份,蛇床子10~20份,覆盆子10~20份,鱼腥草10~20份,白芷10~20份,苦参10~20份,穿心莲10~20份。
3.根据权利要求1所述治疗慢性子宫内膜炎的中药栓剂,其特征在于,所述中药栓剂中各种原料的重量份数包括:丹参10~20份,三棱10~20份,鸡血藤10~20份,益母草10~20份,败酱草10~20份,红藤10~20份,赤芍10~20份,莪术10~20份,蒲公英10~20份,黄芩10~15份,菟丝子10~15份,青黛10~15份,蛇床子10~15份,覆盆子10~15份,鱼腥草10~15份,白芷10~15份,苦参10~15份,穿心莲10~15份。
4.一种如权利要求1~3中任一项所述治疗慢性子宫内膜炎的中药栓剂的制备方法,其特征在于,所述栓剂的制备步骤包括:将所述原料药除白芷与青黛外,其余加水浸泡30分钟至1小时,加热煮沸30~40分钟,过滤,滤液备用;滤渣加水,第二次加热,煮沸30~40分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸30~40分钟,过滤;将三次滤液合在一起,加热浓缩至膏状,再将白芷、青黛用水蒸汽蒸馏法提取,得结晶物,混在上述得到的药膏里;选取基质50℃~60℃加热融化,加入上述得到的药膏冷却定型制成类弹头状栓剂,紫外线杀毒。
5.根据权利要求1~4中任一项所述治疗慢性子宫内膜炎的中药栓剂的制备方法,其特征在于,所述栓剂所用的基质选自:半合成脂肪酸甘油酯、泊洛沙姆、聚乙二醇、羊毛脂中的一种或多种;所述基质在温度50℃~60℃条件下加热融化,加入所述制备方法制得的药物膏体,水浴搅拌均匀,混合成粘稠的液体,灌注在塑料定型管内,插入棉栓,冷却定型制成子弹头状栓剂;所述棉栓为尾部带有棉线的棉栓。
6.一种如权利要求1~3中任一项所述治疗慢性子宫内膜炎的中药栓剂的制备方法,其特征在于,所述栓剂的制备过程进一步包括:
a.将所述原料药除白芷和青黛外放入粉碎机粉碎后过筛,
b.将过筛后剩下的颗粒物放入乙醇中加热回流提取2次;
c.再取上述乙醇提取后的药渣,加水加热回流提取2次;
d.将青黛与白芷蒸馏汽化得结晶,加入上述两种提取液中,基质调和罐装定型,紫外线杀毒。
7.根据权利要求6所述栓剂的制备方法,其特征在于,所述步骤a中,将所述原料药除白芷与青黛外放入粉碎机粉碎后过100-120目细筛,使能通过细筛的细粉量在达到30%,收集通过细筛的原料细粉备用。
8.根据权利要求6所述栓剂的制备方法,其特征在于,所述步骤b中,将过筛后剩下的颗粒物放入乙醇中加热回流提取2次,每次1~2小时,将2次提取液合并静置;
9.根据权利要求6所述栓剂的制备方法,其特征在于,所述步骤c中,将上述乙醇提取过的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置。
10.根据权利要求6所述栓剂的制备方法,其特征在于,所述步骤d中将青黛与白芷蒸馏汽化得结晶,干燥成粉末;再将上述两种提取液合并,减压浓缩相对密度为80℃时1.37的滤液,回收乙醇,将所得滤液调整比重到1.06,加入过筛的细粉和结晶粉末后搅匀,倒入基质中,50℃~60℃加热融化,冷却定型制成类弹头状栓剂,所述粉剂中成药与基质的配比为1∶2~1∶4;所述棉栓为尾部带有棉线的棉栓。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410620655.9A CN104367946A (zh) | 2014-11-06 | 2014-11-06 | 一种治疗慢性子宫内膜炎的中药栓剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410620655.9A CN104367946A (zh) | 2014-11-06 | 2014-11-06 | 一种治疗慢性子宫内膜炎的中药栓剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104367946A true CN104367946A (zh) | 2015-02-25 |
Family
ID=52547306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410620655.9A Pending CN104367946A (zh) | 2014-11-06 | 2014-11-06 | 一种治疗慢性子宫内膜炎的中药栓剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104367946A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104958703A (zh) * | 2015-07-17 | 2015-10-07 | 战汪涛 | 用于治疗羊慢性子宫内膜炎的药物组合物及其制备方法 |
CN113813346A (zh) * | 2021-11-06 | 2021-12-21 | 张春梅 | 一种妇科外用药丸及其包裹工艺和制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1517115A (zh) * | 2003-01-18 | 2004-08-04 | 王光辉 | 治疗慢性盆腔炎的中成药——妇炎胶囊 |
CN101129897A (zh) * | 2007-09-24 | 2008-02-27 | 北京艺信堂医药研究所 | 一种治疗子宫内膜炎的中成药 |
CN101647967A (zh) * | 2009-09-21 | 2010-02-17 | 路平 | 一种治疗子宫内膜炎的中药制备方法 |
-
2014
- 2014-11-06 CN CN201410620655.9A patent/CN104367946A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1517115A (zh) * | 2003-01-18 | 2004-08-04 | 王光辉 | 治疗慢性盆腔炎的中成药——妇炎胶囊 |
CN101129897A (zh) * | 2007-09-24 | 2008-02-27 | 北京艺信堂医药研究所 | 一种治疗子宫内膜炎的中成药 |
CN101647967A (zh) * | 2009-09-21 | 2010-02-17 | 路平 | 一种治疗子宫内膜炎的中药制备方法 |
Non-Patent Citations (3)
Title |
---|
傅立红等: "子宫内膜炎的中医药治疗研究概况", 《中医药学看》 * |
史润果: "中西医结合治疗子宫内膜炎106例", 《中国民间疗法》 * |
姜劲挺等: "《中医脊柱相关疾病学》", 30 April 2012, 甘肃文化出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104958703A (zh) * | 2015-07-17 | 2015-10-07 | 战汪涛 | 用于治疗羊慢性子宫内膜炎的药物组合物及其制备方法 |
CN113813346A (zh) * | 2021-11-06 | 2021-12-21 | 张春梅 | 一种妇科外用药丸及其包裹工艺和制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103721131B (zh) | 一种治疗妇女慢性盆腔炎的中药栓剂及其制备方法 | |
CN102847063B (zh) | 一种治疗气血两虚血瘀型糖尿病足的中药组合物及其制备方法 | |
CN102178804B (zh) | 一种治疗肛周湿疹的中药组合物及其制备方法 | |
CN103751663B (zh) | 一种治疗肛周湿疹的中药外用制剂及其制备方法 | |
CN104274788A (zh) | 一种治疗妇女肝火湿热型带下的中药组合物及其制备方法 | |
CN102178877B (zh) | 一种治疗阴囊湿疹的外用制剂及其制备方法 | |
CN103520439B (zh) | 一种治疗热毒蕴结型慢性骨髓炎的中药及其制备方法 | |
CN100368008C (zh) | 一种治疗妇科疾病的中药及其制备工艺 | |
CN104906465A (zh) | 一种治疗妇女慢性盆腔炎的中药化瘀组合物及其制备方法 | |
CN101637552B (zh) | 一种防治慢性盆腔炎的中药组合物 | |
CN104587302A (zh) | 一种治疗急性阑尾炎的中药制剂 | |
CN104306637A (zh) | 一种治疗妇女脾虚湿盛型带下的中药组合物及其制备方法 | |
CN104367946A (zh) | 一种治疗慢性子宫内膜炎的中药栓剂及其制备方法 | |
CN105362839A (zh) | 一种治疗妇科炎症的中药组合物 | |
CN104324330A (zh) | 一种治疗淤血蓄结型子宫肌瘤的中药组合物及其制备方法 | |
CN103721138A (zh) | 一种治疗酒糟鼻的中药外用制剂及其制备方法 | |
CN103070995A (zh) | 一种治疗前列腺炎的中药 | |
CN103599379B (zh) | 一种治疗肝肾亏虚型慢性骨髓炎的中药及其制备方法 | |
CN106038802A (zh) | 治疗妇女卵巢早衰的中药组合物制备方法及其组合物 | |
CN102526620A (zh) | 一种治疗妇科炎症的中药组合物及应用 | |
CN104352910A (zh) | 一种治疗妇女带下的中药外用栓剂及其制备方法 | |
CN104758754A (zh) | 一种治疗肾气虚衰型前列腺增生的药物及制备方法 | |
CN103721191A (zh) | 一种治疗妇女慢性盆腔炎的中药灌肠剂及其制备方法 | |
CN104127737A (zh) | 用于防治痔疮术后并发症的药物组合物及其制备方法 | |
CN104324185A (zh) | 一种治疗白带过多的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150225 |